--- title: "Antengene appoints Bing Hou as chief scientific officer" type: "News" locale: "en" url: "https://longbridge.com/en/news/286978436.md" description: "Antengene has appointed Bing Hou as chief scientific officer, effective May 19, 2026. He will oversee drug discovery and R&D efforts, reporting to CEO Jay Mei. Hou, who joined Antengene in 2019, previously served as vice president of discovery science. He holds a PhD in biomedicine and has over 40 patent applications." datetime: "2026-05-20T00:00:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286978436.md) - [en](https://longbridge.com/en/news/286978436.md) - [zh-HK](https://longbridge.com/zh-HK/news/286978436.md) --- # Antengene appoints Bing Hou as chief scientific officer - Antengene appointed Bing Hou as chief scientific officer on May 19, 2026, reporting to founder, chairman and CEO Jay Mei. \* Hou will lead drug discovery, translational medicine, and chemistry, manufacturing and controls, with a mandate to deepen internal R&D and build a next-generation pipeline. \* He joined Antengene in 2019, most recently serving as vice president and head of discovery science and translational medicine, where he built the discovery organization and advanced internally discovered programs into clinical development. \* Hou holds a PhD in biomedicine from the University of Leeds and has published in journals including Nature and Science Advances, with more than 40 patent applications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605192000PR\_NEWS\_USPR\_\_\_\_\_CN62873) on May 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ### Related Stocks - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [IXJ.AU](https://longbridge.com/en/quote/IXJ.AU.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [06996.HK](https://longbridge.com/en/quote/06996.HK.md) ## Related News & Research - [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md) - [](https://longbridge.com/en/news/286807703.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [](https://longbridge.com/en/news/286787081.md) - [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)